Liposomal Daunorubicin and SU5416 in Treating Patients With Hematologic Cancer That Has Not Responded to Initial Therapy
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I/II trial to study the effectiveness of liposomal daunorubicin and SU5416 in treating
patients who have hematologic cancer that has not responded to initial therapy. Drugs used in
chemotherapy use different ways to stop cancer cells from dividing so they stop growing or
die. SU5416 may stop the growth of hematologic cancer by stopping blood flow to the cancer